Enhanced Benzathine Analogs for Inflammatory Disorder Treatment
Legal Citation
Summary of the Inventive Concept
The inventive concept discloses novel benzathine analogs and systems that improve the treatment of inflammatory disorders, enhancing bioavailability, reducing sepsis onset, and combating antibiotic resistance.
Background and Problem Solved
The original patent's benzathine analogs demonstrated effectiveness in treating inflammatory disorders, but limitations included variable bioavailability, potential for sepsis onset, and risk of antibiotic resistance. The new inventive concept addresses these limitations by introducing carrier agents, diagnostic tools, and co-administered antibiotics to enhance treatment outcomes.
Detailed Description of the Inventive Concept
The new claims introduce a system comprising a benzathine analog and a carrier agent, which enhances bioavailability by at least 20%. A method for reducing sepsis onset involves administering the benzathine analog and monitoring cytokine levels to adjust dosage. A pharmaceutical composition for treating pneumonia combines the benzathine analog with an antibacterial agent. A system for personalized treatment utilizes a diagnostic tool to determine cytokine profiles and recommend dosages. Finally, a method for reducing antibiotic resistance co-administers the benzathine analog with an antibiotic.
Novelty and Inventive Step
The new claims provide a novel combination of benzathine analogs with carrier agents, diagnostic tools, and antibiotics, which enhances treatment outcomes and addresses the limitations of the original patent. The inventive step lies in the integration of these components to achieve improved bioavailability, reduced sepsis onset, and decreased antibiotic resistance.
Alternative Embodiments and Variations
Alternative embodiments may include different carrier agents, diagnostic tools, or antibiotics. Variations could involve adjusting the dosage or administration schedule of the benzathine analog, or using different benzathine analogs with varying potency.
Potential Commercial Applications and Market
The enhanced benzathine analogs and systems have significant commercial potential in the treatment of inflammatory disorders, particularly in the areas of sepsis and pneumonia. The target market includes pharmaceutical companies, hospitals, and research institutions focused on developing innovative treatments for these disorders.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical chemistry, specifically immunopharmacology and inflammatory disorder treatment, with expertise in drug design, pharmacokinetics, and cytokine modulation
Person of Ordinary Skill (PHOSITA) Profile
A researcher or pharmaceutical scientist with advanced degree (PhD/MD), experience in drug development, knowledge of inflammatory mechanisms, familiarity with drug delivery systems and combination therapies
Obviousness Rationale
A PHOSITA would recognize that enhancing bioavailability, personalizing dosage, and combining benzathine analogs with carrier agents or antibiotics are predictable extensions of the source patent's core teachings about treating inflammatory disorders. The technical variations represent standard optimization strategies in pharmaceutical development, leveraging known techniques for improving drug efficacy and patient outcomes.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,550 |
|---|---|
| Title | Benzathine analogs |
| Assignee(s) | UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, United States Government As Represented By The Department Of Veterans Affairs |